MedTrace Logo

Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin

NCT01871558 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2016-04-21

Study results available
· View outcomes & findings →

Summary

To compare a therapeutic strategy combining vildagliptin+metformin + Basal Insulin versus SU+metformin + Basal Insulin on the incidence of hypoglycemic events over 24 weeks.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

Vildagliptin

50 mg b.i.d

DRUG

Metformin

metformin is to be kept unchanged

DRUG

sulfonylurea (SU)

DRUG

Basal Insulin

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01871558 on ClinicalTrials.gov